HC Wainwright & Co. Reiterates Buy on Syros Pharmaceuticals, Maintains $6 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for Syros Pharmaceuticals, maintaining a price target of $6.
November 01, 2024 | 11:22 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Syros Pharmaceuticals, maintaining a price target of $6.
The reiteration of a Buy rating and maintenance of a $6 price target by HC Wainwright & Co. is a positive signal for investors, suggesting confidence in Syros Pharmaceuticals' future performance. This could lead to increased investor interest and potentially a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100